Category Archives: Cancer REsearch

How Eric Lefkofsky Is Focusing Research And Treatment On Cancer Survivors

At the mention of the word cancer, everybody flinches. Yes! That is how bad it has gotten with the deadly disease in today’s world. It has been decades now, and the scientists are yet to come up with a viable … Continue reading

Posted in Cancer REsearch, Treatment | Leave a comment


“Fail early, fail fast, fail often.” A mantra repeated by many – its origins unknown. Only the bold and unafraid see failure as a new beginning to forge a new success.Greek mythology is a primal source of knowledge. For instance, … Continue reading

Posted in Business Leader, Cancer REsearch | Leave a comment

Cancer Treatment Advances at Seattle Genetics

Cancer is one of the most devastating of all diseases. It takes thousands of lives each year and costs millions of dollars to treat. One of the most exciting companies to attack this problem is Seattle Genetics, located in Seattle, Washington. This company was co-founded in 1998 by Dr. Clay Siegall. He is currently President, Chairman of the Board and CEO. Using the latest biotechnology, their aim is to use a direct treatment method, which will kill only the cancer cells while protecting the non-cancer ones. This technique is designed to reduce the deadly results of traditional chemotherapy. Anti-body conjugates are their main product and include Adcetris, which is used for various types of lymphoma. These anti-body conjugates were developed jointly with Takeda Pharmaceutical Company Limited. Dr. Siegall is well known in the medical field for his work in cancer research. After receiving a Ph.D in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland he became interested in improving current cancer treatment methods. Previous to founding Seattle Genetics, he worked for PDL Biopharma, MedImmune, the National Cancer Institute, Genentech, Curagen Corporation, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Institutes of Health. Dr. Clay Siegall’s dedication to improving cancer treatment has been recognized with numerous awards such as University of Maryland Alumni of the Year and Pacific Northwest Ernst & Young Entrepreneur of the Year. He is a well-known author with over 70 publications, holds a number of patents and currently is a member of the Board of Directors of Alder BioPharmaceuticals.

Posted in Cancer REsearch | Leave a comment

Innovative and Compassionate Therapies for Cancer Patients: Seattle Genetics

Seattle Genetics is a leading biotechnology company, paving the way for innovative cancer therapies. They are an industry leader in anti-body drug conjugates (ADCs), which is a technology that manipulates the targeting ability of monoclonal anti-bodies. These ADCs will deliver cell killing agents directly to cancer cells. This cutting edge therapy is intended to lessen the debilitating effects of chemotherapy. In addition to this major product, they are researching other products to met the needs of cancer therapies. They are advancing new and innovative therapies with less harmful effects on patients. They value research, scientific excellence, and teamwork. These values are reflected through their new and breakthrough products. They are currently in trials for several new therapies, such as lymphoma, leukemia, and solid tumors.  Seattle Genetics shows their excellence through the success of the therapies and improving the lives of patients. Dr. Clay Siegall, who co-founded Seattle Genetics in 1998, is currently the President, CEO, and Chairman of the board. He brought his experience from industry giants, like National Institute of Health and National Cancer Institute. He has helped the company earn 1.2 billion in 2001, and the company made IPO that year. Clay Siegall has helped through a partnership with Takeda Pharmaceuticals to secure a patent for its first ADC product, Adcetris. He continues to push the company to the next level of scientific innovation. Learn more about Doctor Siegall

Posted in Cancer REsearch | 1 Comment